SG11202103073SA - Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides - Google Patents

Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides

Info

Publication number
SG11202103073SA
SG11202103073SA SG11202103073SA SG11202103073SA SG11202103073SA SG 11202103073S A SG11202103073S A SG 11202103073SA SG 11202103073S A SG11202103073S A SG 11202103073SA SG 11202103073S A SG11202103073S A SG 11202103073SA SG 11202103073S A SG11202103073S A SG 11202103073SA
Authority
SG
Singapore
Prior art keywords
deliverability
tolerability
efficacy
compositions
methods
Prior art date
Application number
SG11202103073SA
Other languages
English (en)
Inventor
Dat Tran
Justin B Schaal
Patti Tran
Michael E Selsted
Original Assignee
Dat Tran
Justin B Schaal
Patti Tran
Michael E Selsted
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dat Tran, Justin B Schaal, Patti Tran, Michael E Selsted filed Critical Dat Tran
Publication of SG11202103073SA publication Critical patent/SG11202103073SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0017—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11202103073SA 2018-10-09 2019-10-09 Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides SG11202103073SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862743243P 2018-10-09 2018-10-09
PCT/US2019/055362 WO2020076925A1 (en) 2018-10-09 2019-10-09 Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides

Publications (1)

Publication Number Publication Date
SG11202103073SA true SG11202103073SA (en) 2021-04-29

Family

ID=70164024

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103073SA SG11202103073SA (en) 2018-10-09 2019-10-09 Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides

Country Status (12)

Country Link
US (1) US20210346463A1 (es)
EP (1) EP3863607A4 (es)
JP (2) JP2022502472A (es)
KR (1) KR20210055792A (es)
CN (2) CN113164390A (es)
AU (1) AU2019356916B2 (es)
BR (1) BR112021006643A8 (es)
CA (1) CA3115770C (es)
IL (1) IL282199A (es)
MX (1) MX2021003574A (es)
SG (1) SG11202103073SA (es)
WO (1) WO2020076925A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240108702A1 (en) 2021-01-20 2024-04-04 The University Of Southern California Use Of Naturally Occurring Cyclic Peptides For Treatment Of SARS-COV-2 Infection
WO2023097211A1 (en) * 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002240137A1 (en) * 2001-01-30 2002-08-12 University Of Iowa Research Foundation Antiviral activities of primate theta defensins and mammalian cathelicidins
US20060287221A1 (en) * 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
PT3300721T (pt) * 2003-11-20 2019-06-06 Novo Nordisk As Formulações peptidicas contendo propileno glicol que sao ideais para a produção e para utilizacao em dispositivos de injeção
CN109248310B (zh) * 2011-06-02 2022-07-01 加利福尼亚大学董事会 利用θ-防御素的炎性蛋白酶的阻断
WO2013007596A2 (en) * 2011-07-08 2013-01-17 Novozymes A/S Oral treatment of inflammatory bowel disease
WO2016059593A1 (en) * 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of protein drugs and process for its preparation
WO2017027411A1 (en) * 2015-08-07 2017-02-16 The Regents Of The University Of California Compositions and methods for inhibiting pro-inflammatory cytokine gene expression

Also Published As

Publication number Publication date
AU2019356916A1 (en) 2021-05-06
KR20210055792A (ko) 2021-05-17
JP2022502472A (ja) 2022-01-11
CN113164390A (zh) 2021-07-23
JP2023133565A (ja) 2023-09-22
IL282199A (en) 2021-05-31
WO2020076925A1 (en) 2020-04-16
BR112021006643A2 (pt) 2021-07-20
CA3115770A1 (en) 2020-04-16
AU2019356916B2 (en) 2022-12-01
CN117379529A (zh) 2024-01-12
MX2021003574A (es) 2021-08-27
EP3863607A1 (en) 2021-08-18
BR112021006643A8 (pt) 2022-12-06
EP3863607A4 (en) 2022-07-06
CA3115770C (en) 2023-11-14
US20210346463A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
IL276464A (en) Methods and preparations for administering therapeutic protein
EP3725771A4 (en) ALK PROTEIN DEGRADATION AGENT AND ITS ANTITUMOR APPLICATION
IL273948A (en) Preparations and methods for the selective degradation of proteins
EP3675639A4 (en) PROCESS AND COMPOSITIONS FOR THE PREPARATION OF BACTERIOCINES AND ANTIMICROBIAL PEPTIDES
IL276169A (en) Peptide YY pharmacological formulations, compositions and methods
EP3268050A4 (en) Pore-forming protein conjugate compositions and methods
IL265796A (en) Preparations comprising short peptides derived from pedf and their uses
EP3595699A4 (en) CARTILLE HOMING PEPTIDE CONJUGATES AND METHOD OF USING THEREOF
IL287082A (en) Methods and preparations for targeted unloading of proteins
IL282199A (en) Preparations and methods for improving the systemic transferability, tolerability and efficiency of cationic macrocyclic peptides
EP3642219A4 (en) PEPTIDE COMPOSITIONS AND RELATED PROCEDURES
EP3576764A4 (en) KRAS PEPTIDE VACCINE COMPOSITIONS AND METHOD OF USE
EP3861979A4 (en) COMPOSITION WITH INDUCED EXOSOME FOR HAIR REGENERATION
EP3688011A4 (en) PEPTIDE COMPOSITIONS AND METHOD FOR THEIR USE
EP3626241A4 (en) N-BENZOLSULFONYLBENZAMIDE COMPOUND FOR INHIBITING BCL-2 PROTEIN AND COMPOSITION AND USE THEREOF
ZA201908603B (en) Hair compositions for damage treatment
EP3697422A4 (en) CELL-PENETANT PEPTIDES FOR ANTISENSE RELEASE
EP4069274A4 (en) PEPTIDE CONJUGATES AND METHODS OF USE
IL276888A (en) Pharmaceutical compositions containing timolol
IL265831A (en) Preparations and methods for protein expression and administration
EP3377085A4 (en) PEPTIDES AND METHODS FOR TREATING ENDOMETRIOSIS USING THE SAME PEPTIDES
IL267569B2 (en) Peptides for the treatment of age-related macular degeneration, preparations containing them and their uses
EP3576799A4 (en) OPHTHALMIC COMPOSITIONS FOR THERAPY AND PROPHYLAXIS
AU2017313589B2 (en) Conjugate of minoxidil and peptide
EP3893894A4 (en) MODIFIED NETRIN-1 PEPTIDES AND COMPOSITIONS FOR CARDIOPROTECTION